This study aims to explore how young adults, older adults and people with Parkinson's disease (PwP), perceive their abilty to cross obstacles while walking, and how this perception is related to their actual performance of obstacle crossing and disease-related motor and cognitive impairments. The study will explore this percepeption and the actual performance in different walking environments(floor, synthetic grass turf). Understanding how people perceive obstacles may help improve rehabilitation methods and reduce the risk of falls. The study will take place at the Motor Performance Laboratory, University of Haifa, and will include walking tasks, eye-tracking measurements, and motor and cognitive assessments.
This study investigates the role of affordance perception - the ability to perceive opportunities for action - during obstacle crossing in people with Parkinson's disease (PwP). Falls are highly prevalent in PwP, often resulting from tripping over obstacles. While previous research has mainly focused on gait impairments, this study uniquely examines the perceptual stage that precedes movement and the association between perception, cognition, and motor performance. Participants will include 60 PwP and 120 healthy adults (60 older adults and 60 young adults). All participants will perform walking tasks involving obstacle crossing under different environmental conditions (e.g., different obstacle heights and surfaces). Prior to walking, participants will judge whether they can safely cross the obstacle. Eye-tracking glasses will measure visual exploration patterns to assess how participants scan the environment. Additionally, walking variables such as speed and step length, will be recorded using wearable sensors. The study will explore: 1. Differences in affordance perception between PwP and healthy adults. 2. Associations between motor and cognitive impairments and affordance perception in PwP. 3. How affordance perception relates to gait performance during obstacle crossing. Results from this study may help to develop new intervention strategies aimed at improving safe walking and obstacle negotiation in PwP.
Study Type
OBSERVATIONAL
Enrollment
180
Participants will perform walking tasks involving obstacle crossing while their gait and visual exploration patterns are recorded using wearable sensors and eye-tracking glasses. This is a non-invasive observational study with no therapeutic intervention.
University of Haifa, Motor Performance Laboratory
Haifa, Israel
RECRUITINGAffordance Perception Accuracy
Accuracy of participants' perception of their ability to cross obstacles of varying height and surface conditions. Participants will judge whether they can safely cross an obstacle prior to walking.
Time frame: During single laboratory session (about 3 hours)
Affordances measured by gaze behavior
Eye movement patterns during obstacle approach and crossing. Gaze behavior will be recorded using wearable eye-tracking glasses (Tobii Pro Glasses 3) to assess visual exploration of the walking environment and obstacle. Measures will include fixation(on obstacle) duration (milisecondes).
Time frame: During a single laboratory session (approximately 3 hours)
Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Disease severity will be assessed using the MDS-UPDRS (Motor Examination). This standardized clinical assessment measures motor symptoms in people with Parkinson's disease, including tremor, rigidity, bradykinesia, and postural stability. Higher scores indicate greater motor impairment.
Time frame: During a single laboratory session (approximately 3 hours)
Walking Speed
Walking speed during obstacle crossing tasks, measured using wearable sensors (APDM Mobility Lab). Walking speed will be calculated in meters per second based on time and distance walked during the trials.
Time frame: During a single laboratory session (approximately 3 hours)
Step Length
Step length during obstacle crossing tasks, measured using wearable sensors (APDM Mobility Lab). Step length will be calculated in meters for each leg during walking trials, as an indicator of gait characteristics and stability.
Time frame: During a single laboratory session (approximately 3 hours)
Levodopa Equivalent Daily Dose (LEDD)
The total daily dose of antiparkinsonian medications will be calculated for participants with Parkinson's disease using the standardized Levodopa Equivalent Daily Dose (LEDD) formula. Higher values indicate greater medication use.
Time frame: During a single laboratory session (approximately 3 hours)
Cognitive Performance - Stroop Test (NeuroTrax Cognitive Battery)
Cognitive function will be assessed using the computerized NeuroTrax Cognitive Battery. Specifically, performance on the Stroop test will be used to evaluate executive function, focusing on response inhibition and attention control. The Stroop test provides accuracy and reaction time scores, with higher scores reflecting better performance.
Time frame: During a single laboratory session (approximately 3 hours)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.